Contact Us
 • 
Home
Search 

ECMC Trial Portfolio

Select Disease Group:

 

All Solid Tumours

Project Title Website PI Recruitment Contact

 

A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors

 

Disposition of[14C]Pamiparib in Patients with Tumours Prof D Palmer 2 Send E-mail

 

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors

 

REPLIMUNE Dr J Sacco 4 Send E-mail
  6  

 

Back to top

 

 

Breast

Project Title Website PI Recruitment Contact

 

A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening

 

plasmaMATCH Prof C Palmieri 7 Send E-mail
  7  

 

Back to top

 

 

Haematology

Project Title Website PI Recruitment Contact

 

AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)

 

AVAIL-T Dr. A. Arumainathan 1 Send E-mail

 

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI0610 with and without Ruxolitinib in Patients with Myelofibrosis)

 

MANIFEST Dr. N. Butt 0 Send E-mail

 

RomiCar - Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma

 

RomiCAR Dr. N . Kalakonda 1 Send E-mail

 

Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

 

TIDaL Dr A. Arumainathan 2 Send E-mail
  4  

 

Back to top

 

Head & Neck

Project Title Website PI Recruitment Contact

 

Cambridge Brain Mets Trial 1: A proof­ of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low­-dose, targeted radiotherapy

 

CamBMT1 Dr B Haylock 0 Send E-mail

 

NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer

 

NICO Dr A Haridass 0 Send E-mail

 

A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer

 

WISTERIA: WEE1 inhibitor with Cisplatin and Radiotherapy Dr J Sacco 1 Send E-mail
  1

 

Back to top

 

 

HPB / Upper GI

Project Title Website PI Recruitment Contact

 

ACIT I: A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients

 

ACIT-1 Prof. D Palmer 21 Send E-mail

 

BLU 554: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma

 

BLU-554 / CANC 4809 Prof. D Palmer 2 Send E-mail

 

OUTREACH: A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)

 

OUTREACH / CANC 4818 Prof. D Palmer 4 Send E-mail

 

Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

 

Phase 1-2 Study of ADI plus FOLFOX in GI cancer focusing on HCC Prof. D Palmer 0 Send E-mail
  27  

 

Back to top

 

Lung

Project Title Website PI Recruitment Contact

 

The Cancer Research UK Stratified Medicine Programme: Pilot Study

 

CR UK Stratified Medicine Pilot study Dr. Carles Escriu 52 Send E-mail
  52  

 

Back to top